TARSUS PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TARSUS PHARMACEUTICALS, INC. (TARS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $13.29M, a 61.39% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $11.97M, a 72.68% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $12.24M, a 65.11% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $8.23M, a 10.07% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $41.72M, a 49.97% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.82M, a 40.28% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $19.83M, a 47.33% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $13.46M, a 59.20% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.29M 10-Q · filed 2026-08-06 | $25.26M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $11.97M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $41.72M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $12.24M 10-Q · filed 2025-11-04 | $20.48M derived: sum of 2 quarters · filed 2026-08-06 | $27.41M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $8.23M 10-Q · filed 2026-08-06 | $15.16M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $6.93M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $27.82M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $7.42M 10-Q · filed 2025-11-04 | $14.90M derived: sum of 2 quarters · filed 2025-11-04 | $20.41M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $7.48M 10-Q · filed 2025-11-04 | $13.00M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $5.52M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $19.83M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $5.25M 10-Q · filed 2024-11-13 | $10.44M derived: sum of 2 quarters · filed 2024-11-13 | $14.35M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $5.19M 10-Q · filed 2024-11-13 | $9.10M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $3.91M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $13.46M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $3.58M 10-Q · filed 2023-11-09 | $7.12M derived: sum of 2 quarters · filed 2023-11-09 | $9.79M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $3.53M 10-Q · filed 2023-11-09 | $6.21M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $2.67M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $8.46M 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $2.12M 10-Q · filed 2022-11-09 | $4.91M derived: sum of 2 quarters · filed 2022-11-09 | $6.28M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $2.79M 10-Q · filed 2022-11-09 | $4.16M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.36M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $839.00K 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $223.00K 10-Q · filed 2021-11-10 | $396.00K derived: sum of 2 quarters · filed 2021-11-10 | $400.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $173.00K 10-Q · filed 2021-11-10 | $177.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $4.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $18.00K 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $5.00K 10-Q · filed 2020-11-25 | $10.00K derived: sum of 2 quarters · filed 2020-11-25 | $14.00K derived: sum of 3 quarters · filed 2020-11-25 | |
| 2019-06-30 | $5.00K 10-Q · filed 2020-11-25 | $9.00K derived: sum of 2 quarters · filed 2020-11-25 | ||
| 2019-03-31 | $4.00K 10-Q · filed 2020-11-25 | |||
| 2018-12-31 | $9.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |